Mechanistic Target of Rapamycin Complex 2
"Mechanistic Target of Rapamycin Complex 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A multiprotein complex consisting of MTOR KINASE; MLST8 PROTEIN; rapamycin-insensitive companion of mTOR protein (RICTOR PROTEIN); and PRR5 (proline-rich protein 5). Like MTORC1, it also regulates cell growth and proliferation in response to growth factors but may not be as sensitive to nutrient availability and is insensitive to SIROLIMUS. In contrast to MTORC1, it can regulate the ACTIN CYTOSKELETON through RHO GTPASES to promote the formation of STRESS FIBERS. The mTORC2 complex also plays a critical role in AKT1 PROTEIN KINASE phosphorylation and activation.
| Descriptor ID |
D000076225
|
| MeSH Number(s) |
D05.500.356 D08.811.913.696.620.682.700.931.750 D12.776.476.925.750
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Mechanistic Target of Rapamycin Complex 2".
Below are MeSH descriptors whose meaning is more specific than "Mechanistic Target of Rapamycin Complex 2".
This graph shows the total number of publications written about "Mechanistic Target of Rapamycin Complex 2" by people in this website by year, and whether "Mechanistic Target of Rapamycin Complex 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 2 | 2 |
| 2015 | 0 | 4 | 4 |
| 2016 | 0 | 2 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 2 | 3 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mechanistic Target of Rapamycin Complex 2" by people in Profiles.
-
Targeted suppression of mTORC2 reduces seizures across models of epilepsy. Nat Commun. 2023 11 14; 14(1):7364.
-
Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay. Cardiovasc Drugs Ther. 2020 08; 34(4):443-461.
-
Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. Nat Commun. 2020 07 22; 11(1):3669.
-
HEM1 deficiency disrupts mTORC2 and F-actin control in inherited immunodysregulatory disease. Science. 2020 07 10; 369(6500):202-207.
-
Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors. Clin Cancer Res. 2020 09 01; 26(17):4633-4642.
-
Therapeutic inhibition of mTORC2 rescues the behavioral and neurophysiological abnormalities associated with Pten-deficiency. Nat Med. 2019 11; 25(11):1684-1690.
-
Activating Transcription Factor 4 Modulates TGF?-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling. Clin Cancer Res. 2018 11 15; 24(22):5697-5709.
-
Opposing Tumor-Promoting and -Suppressive Functions of Rictor/mTORC2 Signaling in Adult Glioma and Pediatric SHH Medulloblastoma. Cell Rep. 2018 07 10; 24(2):463-478.e5.
-
mTORC2, but not mTORC1, is required for hippocampal mGluR-LTD and associated behaviors. Nat Neurosci. 2018 06; 21(6):799-802.
-
Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Na?ve Advanced Pancreatic Neuroendocrine Tumors. Oncologist. 2018 07; 23(7):766-e90.